Everything below concerns Insulin-like growth factor 1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
CEEs are a combination of estrogens, or agonists of the estrogen receptors. The major estrogen in CEEs, sodium estrone sulfate, itself is inactive, and rather serves as a prodrug of estrone and then of estradiol. The transformation of estrone sulfate to estrone is catalyzed by steroid sulfatase, and of estrone into estradiol by 17β-hydroxysteroid dehydrogenase. CEEs (as Premarin) and estrone have been found to be equivalent in potency in an animal model of estrogenic activity. On the other hand, the active forms of the equine estrogens in CEEs, such as equilin and 17β-dihydroequilin, have greater potency in the liver relative to bioidentical estradiol, similarly to synthetic estrogens like ethinylestradiol and diethylstilbestrol. This results in disproportionate effects on liver protein production compared to estradiol, although to a lesser extent than ethinylestradiol and diethylstilbestrol. In addition, 17β-dihydroequilenin has shown a selective estrogen receptor modulator (SERM)-like profile of estrogenic activity in studies with monkeys, in which beneficial effects on bone and the cardiovascular system were observed but proliferative responses in breast or endometrium were not seen, although the clinical significance of this is unknown. CEEs consists of the sodium salts of the sulfate esters of equine estrogens in a specific and consistent composition (see the table). The major estrogens in CEEs are sodium estrone sulfate and sodium equilin sulfate, which together account for approximately 71.5–92.0% of the total content of CEEs.
Peitzmeier and colleagues conducted a study on partner violence; they found that transgender individuals are 3 times more likely than their counterparts to experience partner violence physical and sexual. Partner violence is a risk factor for numerous health outcomes like a decrease psychological well-being, a poor sexual health, etc. There is limited data regarding the impact of social determinants of health on transgender and gender non-conforming individuals' health outcomes. However, despite the limited data available, transgender and gender non-conforming individuals have been found to be at higher risk of experiencing poor health outcomes and restricted access to health care due to increased risk for violence, isolation, and other types of discrimination both inside and outside the health care setting. Despite its importance, access to preventive care is also limited by several factors, including discrimination and erasure. A study on young transgender women's access to HIV treatment found that one of the main contributors to not accessing care was the use of incorrect name and pronouns. A meta analysis of the National Transgender Discrimination Survey examined respondents who used the "gender not listed here" option on the survey and their experiences with accessing health care. Over a third of the people who chose that option said that they had avoided accessing general care due to bias and fears of social repercussions.
== Departments == Division of Basic Medical Sciences I Department of Biochemistry Department of General Biology Department of Medical Physics Division of Basic Medical Sciences II Department of Anatomy Department of General Pharmacology Department of Physiology Division of Clinical Laboratories Department of Microbiology Department of Nuclear Medicine Department of Pathology Department of Public Health Department of Radiology Division of Internal Medicine Ι Department of Internal Medicine Division of Paediatrics & Obstetrics – Gynaecology Department of Obstetrics - Gynecology Department of Paediatric Surgery Department of Paediatrics Division of Surgery Department of Anaesthesiology and Intensive Care Department of Cardiothoracic Surgery Department of Neurosurgery Department of Ophthalmology Department of Orthopaedics Department of Otorhinolaryngology Department of Surgery Department of Urology Department of Vascular Surgery
=== CAT scans === CAT scans can be used to infer the 3D structure of a fossil egg's interior by compiling images taken of slices through the egg in small regular increments. Scientists have tried to use CAT scans to look for embryo fossils contained inside the egg without having to damage the egg itself by physically extracting them. However, as of Ken Carpenter's 1999 book on dinosaur eggs, Eggs, Nests, and Baby Dinosaurs, all alleged embryos discovered using this method were actually false alarms. Variations in the type of infilling mineral or cement binding the infilling sediment into rock sometimes resemble bones in CAT scan images. Sometimes eggshell fragments that fell back into the egg when it hatched have been mistaken for embryonic bones. The use of CAT scans to search for embryonic remains is actually conceptually flawed since embryonic bones have not yet mineralized. Since the infilling sediment is their only source of minerals they will be preserved at basically the same density and therefore have poor visibility in the scan. The validity of this issue has been confirmed by performing Cat scans on fossil eggs known to have embryos inside and noting their poor visibility in the scan images. The only truly reliable way to discover a dinosaur embryo is to cut the egg open or dissolve some of its eggshell away.
In 1957, Polish foreign minister Adam Rapacki proposed the Rapacki Plan for a nuclear free zone in central Europe. Public opinion tended to be favourable in the West, but it was rejected by leaders of West Germany, Britain, France and the United States. They feared it would leave the powerful conventional armies of the Warsaw Pact dominant over the weaker NATO armies. During November 1958, Khrushchev made an unsuccessful attempt to turn all of Berlin into an independent, demilitarized "free city". He gave the United States, Great Britain and France a six-month ultimatum to withdraw their troops from the sectors of West Berlin, or he would transfer control of Western access rights to the East Germans. Khrushchev earlier explained to Mao Zedong that "Berlin is the testicles of the West. Every time I want to make the West scream, I squeeze on Berlin." NATO formally rejected the ultimatum in mid-December and Khrushchev withdrew it in return for a Geneva conference on the German question.
Sources: en.wikipedia.org
==== July 2021 settlement ==== Four major drug manufacturers and distributors, J&J, McKesson, Cardinal Health, and AmerisourceBergen, have agreed to a settlement announced by a group of state attorneys general in July 2021. The settlement, $26 billion (US), will be used on the prevention of opioid addiction and treatment programs. J&J will pay $5 billion (US) over the next five years; the remaining $21 billion (US) will be paid by the other firms. The settlement, when approved by a "significant" group of states and local governments, will settle more than 4,000 individual legal actions. All four of the manufacturing firms disputed all allegations in the lawsuits.
Vulture bees are a small group of obligately necrophagous bees in the Trigona genus. Trigona worker bees play a similar role to worker bees in the Apis genus; however, along with collecting pollen, nectar, and plant resins, Trigona workers also collect carrion. Although pollen is associated with higher energy value, carrion is preferred by Trigona bees because it is biochemically easier to extract energy from. This dead animal tissue is used as a source of amino acids too. Cerumen pots are utilized by some Trigona species, such as T. necrophaga, as vesicles to store foodstuff. The foodstuff of T. necrophaga consists of both honey and carrion from vertebrate carcasses. Ultimately, the stored food is utilized by developing larvae and the worker bee itself as a source of nutrition and energy. Due to the rapid decomposition of carrion, especially in warm temperatures, the bees must efficiently metabolize the carrion to avoid rotten carrion in their cerumen pots. Trigona hypogea communicate the presence of a valuable carcass through olfactory signals. The bees create an odour trail between their nest and the prospective animal carcass; thus, the bees recruit the other nest members to respond and exploit the corpse's resources rapidly. Additionally, interspecific competition is observed in Trigona hypogea bees. The bees are observed to defend their colonized food item, including but not limited to a monkey, lizard, fish, or snake carcass, from competing necrophages, such as flies.
== Causes == In July 2017 Live Science reported Romain Pizzi, the specialist wildlife veterinary surgeon at the Scottish Society for the Prevention of Cruelty to Animals (Scottish SPCA), saying that, "Hedgehogs have a little windpipe that runs from their mouth and nose to their lungs, and at the top of this windpipe is the glottis, which opens and closes as hedgehogs breathe. [...] If a hedgehog is struck when that glottis is open, air simply flows out of the lungs and out of the body. But if the glottis is closed when the animal is struck, that air has nowhere to go, and the lung tissue can rupture. It's like a balloon popping. [...] This trauma can also cause damage to the muscles in between a hedgehog's ribs". Live Science added that "the ruptures in the lungs and rib muscles [according to Pizzi] 'act like a one-way valve,' so air can flow out of the lungs and into the body cavity—but not back in. So, with each breath the hedgehog takes, a bit of air leaks out, causing the hedgehog to inflate itself. [...] Pizzi noted that the tissue under a hedgehog's skin isn't designed to be filled with air, so it's not one big open compartment. Instead, there is a lot of connective tissue under the skin, sectioning areas off into little compartments of air. Though it's called balloon syndrome, in most cases the hedgehogs 'puff up more like Bubble Wrap,' he said".
One domain is a lectin that binds cell surface galactosyl residues and enables the protein to enter cells. The second domain is an N-glycosidase that cleaves nucleobases from ribosomal RNA, resulting in inhibition of protein synthesis and cell death. Abrin from the jequirity pea is similar.
1983 – 1st Pump MiniMed 502 (Eli Lilly makes synthetic insulin) 1985 – MiniMed 504 Insulin Pump 1992 – Launch Of MiniMed 506 Insulin Pump 1996 – Introduction of MiniMed 507 Pump 1999 – Launch of the Model 507C 1999 – Introduction of MiniMed 508 Insulin Pump 2002 – Inauguration of the MiniMed Paradigm 511 2003 – 1st Wireless MiniMed Paradigm 512/712 (followed by 515/715) 2006 – MiniMed Paradigm REAL-Time 522/722 2010 – MiniMed Paradigm REAL-Time Revel 523/723
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.